The iconic rise of Viagra has firmly established as a benchmark of pharmaceutical success, but its position within the broader market now triggers questions about long-term yields . Copycat versions are undercutting patent protection , leading to worries that investing in companies significantly dependent to Viagra's once-dominant position could… Read More